Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Puerto Rico Healthcare Daily.
Press releases published on July 4, 2025
The Dermatology Group of Arkansas Welcomes Double Board-Certified Dermatologist to Practice
GlobeNewswire
·
July 4, 2025
LITTLE ROCK, Ark., July 04, 2025 (GLOBE NEWSWIRE) -- The Dermatology Group of Arkansas are thrilled to welcome their newest, double board-certified specialist, Dr. Jessica Pillow, who joins the Little Rock, skin care-focused practice this summer. Dr. …
Seule la transparence et la responsabilité peuvent sauver le CERN : une condition essentielle pour mettre fin au gaspillage de milliards et accélérer les innovations médicales vitales
GlobeNewswire
·
July 4, 2025
DALLAS, 04 juill. 2025 (GLOBE NEWSWIRE) -- La Crosetto Foundation for the Reduction of Cancer Deaths, une organisation à but non lucratif agréée, lance un « appel urgent aux membres du Parlement européen et des parlements nationaux : il faut geler les …
Chiropractor Posture Correction: Colm Murph of Brighton Chiropractic Office Shares Advice in HelloNation
GlobeNewswire
·
July 4, 2025
Brighton, N.Y., July 04, 2025 (GLOBE NEWSWIRE) -- What are the daily habits that help prevent back pain before it starts? According to Colm Murph, chiropractor and owner of Brighton Chiropractic Office, understanding how posture influences spinal health is …
Sodium Perborate Market worth $184.0 million in 2030, at 3.7%, says MarketsandMarkets™
GlobeNewswire
·
July 4, 2025
Delray Beach, FL, July 04, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Sodium Perborate Market is expected to reach USD 184.0 million in 2030 from USD 153.3 million in 2025, registering a CAGR of 3.7%, as per the recent study by MarketsandMarkets™. …
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
GlobeNewswire
·
July 4, 2025
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with …
AB Science : Le masitinib reçoit l'autorisation de la FDA et de l'EMA pour l’etude confirmatoire de phase 3 dans le cancer de la prostate métastatique hormono-resistant
GlobeNewswire
·
July 4, 2025
COMMUNIQUÉ DE PRESSE LE MASITINIB REÇOIT L'AUTORISATION DE LA FDA ET DE L'EMA POUR L’ETUDE CONFIRMATOIRE DE PHASE 3 DANS LE CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT, AVEC UNE SÉLECTION DES PATIENTS BASÉE SUR DES BIOMARQUEURS CIBLANT LA …